FUJIFILM Diosynth Biotechnologies Newsletter - July 2024
FUJIFILM Diosynth Biotechnologies
Partners for Life, Advancing Tomorrow's Medicines
Latest News
We are proud to announce that the European Medicines Agency (EMA) granted a Certificate of GMP Compliance to our Thousand Oaks, CA site on June 21, 2024. We look forward to providing cell therapy services from this dedicated, growing facility for those looking for a partner to manufacture products intended for the EU. Learn more about how we can support you in addressing the challenges of complex cell therapy development and manufacturing scalability.???
?
Our team recently celebrated the groundbreaking of the $1.2bn expansion at our Holly Springs, North Carolina site. This expansion is a critical component of our Partners for Life 2030 Strategy – representing a significant increase in our commercial capacity in the coming years.? ? ?
Thought Leadership
?
Autoinjectors, traditionally used for diabetes and autoimmune conditions, are now expanding into oncology and metabolic disease markets, empowering patients to manage their treatments at home. FUJIFILM Diosynth Biotechnologies and SHL Medical have partnered to enhance drug delivery solutions, combining SHL's expertise in self-injection devices with our robust manufacturing capabilities. ? ?
Development of a Continuous Electroporation System for Viral Gene Therapy? ? High dose delivery has long been an industry bottleneck, but Fujifilm BSEL is leading the charge with a revolutionary continuous electroporation device. Historically hindered by low throughput and poor cell viability, this new technology promises to eliminate the need for chemically mediated transfection. Set to debut in our Texas demo labs in early 2025, this device is poised to boost vector productivity, streamline manufacturing, and make VGTs more economically viable.?
?
领英推荐
In this video, our Principal Technical Project Leader, Dr. Lee Johnson, shares his thoughts on critical early considerations to ensure process characterization success.?
?
Our Process Development teams leverage extensive knowledge in microbial-based biologic processes, enabling the design of efficient development strategies. Learn more about our Gene-to-Toxicology program, which offers a streamlined set of services to efficiently progress microbial biologics to toxicology trials.???
?
?Upcoming Events
?
BIO Asia-Taiwan?
July 24-28, Taipei, Taiwan?
?
We are delighted to be co-exhibiting at BIO Asia-Taiwan. If you are attending, schedule a meeting with our team via One-to-One partnering, or stop by our booth M208 to learn more about FUJIFILM Diosynth Biotechnologies’ capabilities.?
August 5, 2024, at 11:00 AM EDT
Join us for a webinar on “Transforming Safety in CDMO Operations A Customer Centric Model for Patients and Employees” When considering what’s most important in multimodal CDMOs – do organizations truly operate with a customer mindset or prioritize the health and safety of both workers and patients? Or is it possible to consider that quality and safety are two sides of the same coin, with the customer sitting at the interface of the two? This webinar, led by Dr. AJ Troiano, Director of Biosafety and Toxicology at FUJIFILM Diosynth Biotechnology, will highlight the unique infrastructure FDB has built around safety operations and quality, with a focus on our new product introduction process with respect to risk assessment. Don’t miss out. Register today!